Welcome to our dedicated page for Walker & Dunlop SEC filings (Ticker: WD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Walker & Dunlop, Inc. SEC filings document a NYSE-listed commercial real estate finance company whose common stock trades under WD. Its 8-K filings include quarterly and annual operating results, transaction volume, revenues, mortgage banking activity, servicing portfolio disclosures, and furnished press-release exhibits for financial results.
The company's regulatory documents also cover proxy governance, annual meeting matters, executive compensation disclosures, and capital-structure records. Material-event filings describe financing arrangements used by Walker & Dunlop and its operating subsidiary, Walker & Dunlop, LLC, including amendments to warehousing credit and security agreements and master repurchase agreements that support its commercial real estate lending and mortgage banking operations.
Florkowski Gregory reported acquisition or exercise transactions in this Form 4 filing.
Walker & Dunlop EVP & CFO Gregory Florkowski reported a routine compensation-related transaction. He received 67.857 dividend equivalent rights on June 4, 2026, each economically equivalent to one share of common stock. These rights accrued on his existing restricted stock units and will vest proportionately with those units. Following this grant, he directly holds 248.005 dividend equivalent rights. This is not an open-market stock purchase or sale, but an automatic award tied to prior equity grants.
Walker William M reported acquisition or exercise transactions in this Form 4 filing.
Walker & Dunlop, Inc. reported that Chairman & CEO William M. Walker received a grant of 40.042 dividend equivalent rights on June 4, 2026. Each right is economically equivalent to one share of common stock and accrued on restricted stock units he holds.
After this award, Walker holds a total of 191.8184 dividend equivalent rights. These rights vest proportionately with the related restricted stock units, meaning they follow the same vesting schedule rather than being immediately exercisable.
Wells Donna reported acquisition or exercise transactions in this Form 4 filing.
Walker & Dunlop, Inc. director Donna Wells received a grant of 3,096 deferred stock units. Each unit represents the right to receive one share of Walker & Dunlop common stock. The units vest on the one-year anniversary of the grant date and will be settled in common shares under the company’s Deferred Compensation Plan for Non-Employee Directors.
Walker & Dunlop director Dana L. Schmaltz received equity awards in the form of common stock and deferred stock units. Schmaltz was granted 3,096 shares of restricted common stock under the Walker & Dunlop, Inc. 2024 Equity Incentive Plan, which vest on the one-year anniversary of the grant date. In addition, Schmaltz acquired 2,477 deferred stock units, each representing the right to receive one share of Walker & Dunlop common stock, which are fully vested and will be settled in shares under the company’s Deferred Compensation Plan for Non-Employee Directors. Following these awards, Schmaltz directly holds 87,421 shares of common stock and 2,477 deferred stock units.
Rice E. John Jr reported acquisition or exercise transactions in this Form 4 filing.
Walker & Dunlop director John E. Rice Jr. received a grant of 3,096 shares of restricted common stock as compensation under the company’s 2024 Equity Incentive Plan. These shares vest on the one-year anniversary of the grant date. After this award, he directly owns 36,397 common shares and indirectly holds 55 shares through a trust.
Pinkus Gary S reported acquisition or exercise transactions in this Form 4 filing.
Walker & Dunlop director Gary S. Pinkus received a grant of 3,096 deferred stock units. These units were awarded at no cash cost as director compensation and each unit represents one share of common stock. The award will vest on the one-year anniversary of the grant date and then be settled in Walker & Dunlop common shares in accordance with the company’s Deferred Compensation Plan for Non-Employee Directors.
Levy Ellen reported acquisition or exercise transactions in this Form 4 filing.
Walker & Dunlop, Inc. director Ellen Levy reported receiving a grant of 3,096 deferred stock units on common stock. These units were awarded as compensation, with no cash paid by Levy for the grant. Following the award, she holds 3,096 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of Walker & Dunlop common stock. The units vest on the one-year anniversary of the grant date and will be settled in common shares in accordance with the company’s Deferred Compensation Plan for non‑employee directors.
Hayward Jeffery R reported acquisition or exercise transactions in this Form 4 filing.
Walker & Dunlop, Inc. director Jeffery R. Hayward received a grant of 3,096 shares of common stock at no cost as equity compensation. The award was made under the Walker & Dunlop, Inc. 2024 Equity Incentive Plan and consists of restricted common stock that vests on the one-year anniversary of the grant date. Following this grant, Hayward directly holds 6,712 shares of Walker & Dunlop common stock.
FREEDMAN ERNEST MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Walker & Dunlop, Inc. director Ernest Michael Freedman reported receiving a grant of 3,096 shares of common stock as equity compensation. These shares are described as restricted common stock issued under the Walker & Dunlop, Inc. 2024 Equity Incentive Plan and will vest on the one-year anniversary of the grant date. Following this award, Freedman directly holds 9,193 shares of Walker & Dunlop common stock.
Walker & Dunlop, Inc. reported the final voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders cast between 24.5 million and 26.3 million votes in favor of each of eight director nominees, with comparatively few votes against or abstentions and over 3.0 million broker non-votes on each director item.
On another matter, stockholders cast 28,770,885 votes for, 802,840 against, and 16,838 abstentions. A further item received 18,276,382 votes for, 7,493,052 against, 723,057 abstentions, and 3,098,072 broker non-votes.